Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)

Trial Identifier: D3250R00109
Sponsor: AstraZeneca
Start Date: January 2023
Primary Completion Date: February 2025
Study Completion Date: February 2025
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Taiwan Changhua City, Taiwan
Taiwan Kaohsiung City, Taiwan
Taiwan New Taipei City, Taiwan
Taiwan Tainan City, Taiwan
Taiwan Taipei City, Taiwan
Taiwan Taoyuan City, Taiwan